A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy

Article

Abstract: In the absence of a proven effective vaccine preventing infection by SARS-CoV-2, or a proven drug to

Palabras claves:

antibody-ACE2 fusion, Biparatopic, covid-19, neutralizing antibody, SARS-COV-2

Autores:

Chen C., Chen L., Fu W., Gao W., Huang X., James W.S., Javier Gilbert Jaramillo, Jiang W., Knight M.L., Lee S.M.Y., Liu X., Luo Y., Miao X., Pang T., Rijal P., Song X., Sun J., Tan T.K., Tang Y., Townsend A.R., Tsun A., Wan L., Wang C., Wu F., Xu Y., Yan Y., Yuan Z., Zou Y.

Fuentes:

scopus